Dermatology
Partner With Us
Advertisement
Conexiant chevron_right Dermatology chevron_right Oral TYK2 Inhibition inAtopic Dermatitis
From the Journals

Oral TYK2 Inhibition in Atopic Dermatitis

Phase 2 trial evaluated once-daily oral TYK2 inhibition in adults with moderate to severe AD.

Conexiant
article Full Article subject Summary summarize Notecard
  1. ICP-332 markedly reduced AD severity vs placebo at 4 weeks.
  2. Nearly two-thirds of treated patients achieved EASI-75.
  3. Pruritus improvement occurred within days of treatment.
  4. No serious safety signals were observed.
  5. Results justify phase 3 trials.

Source: JAMA Dermatology

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.